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Abstract: Despite the productivity of basic cancer research, cancer continues to be a health 
burden to society because this research has not yielded corresponding clinical applications. 
Many proposed solutions to this dilemma have revolved around implementing organizational 
and policy changes related to cancer research. Here I argue for a different solution: a new 
conceptualization of causation in cancer. Neither the standard molecular biomarker approaches 
nor evolutionary medicine approaches to cancer fully capture its complex causal dynamics, 
even when considered jointly. These approaches map on to Ernst Mayr’s proximate-ultimate 
distinction, which is an inadequate conceptualization of causation in biological systems and 
makes it difficult to connect developmental and evolutionary viewpoints. I conceptualize 
causation in cancer through the notion of modularity as a bridge between molecular biomarker 
approaches and evolution medicine approaches. A modularity-based approach requires the 
consideration of relationships between multiple levels of organization and the incorporation of 
different time scales, thereby overcoming the proximate-ultimate divide. The proposed 
perspective on causation in cancer is better suited to integrating the complexity of current 
empirical results and can facilitate novel developments in the investigation and clinical treatment 
of cancer. 
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1. Introduction 
 
 Numerous reports of cancer-related research are published each week, yet society 
continues to be underwhelmed by the rate at which discoveries are translated into effective 
clinical applications. In other words, cancer research appears to be progressing, but few new 
treatments or diagnostic and preventive tools have significantly impacted how doctors work 
clinically. Various parties have pointed to different reasons for this situation, including funding 
and institutional barriers. However, the translation failure rates remained high despite the 
doubling of the United States National Institutes of Health (NIH) budget between 1998 and 2003 
(Sarewitz 2013). The NIH, the Canadian Institutes of Health Research (CIHR), and other 
funding organizations have recently emphasized translational research, an endeavor specifically 
focused on translating the knowledge gained at the bench into clinical applications. Much of the 
attention in translational research has been devoted to organizational and policy changes that 
remove barriers to clinical trials, redesign physician-scientist (MD/PhD) programs, and facilitate 
programs that encourage the formation of academic centers for interdisciplinary clinical and 
translational research (e.g., the Clinical Translational Science Awards consortium through the 
NIH). Much less attention has been devoted to whether the core research strategies used by 
translational researchers are adequate for the generation of desired clinical applications. It is 
assumed that the prevailing approaches and frameworks will translate into the clinic eventually, 
given enough time and the right combination of researchers. As I will argue, this is a bad 
assumption and therefore attending to institutional structure and research organization alone will 
be insufficient. Cancer translational research needs a more radical solution. 
 I am not the first to recognize this, nor the first to suggest solutions to this problem. 
Evolutionary and ecological approaches to cancer research emerged in response to the lack of 
clinical applications from the basic biology discoveries (Wodarz 2006; Greaves and Maley 2012; 
see more below), and the parallels between cancers and ecosystems have continued to be 
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elucidated (Merlo et al 2006; Kareva 2015). Physicists and mathematicians were recruited to 
ask questions about cancer in new ways, including using their mathematical and computational 
skills to model and investigate virtual cancer systems (Michor et al 2011; Agus and Michor 
2012; Kuhn and Nagahara 2013). Philosophers also have sought to explain and make sense of 
cancers in novel ways (Bertolaso 2016), such as through multilevel selection (Lean and 
Plutynski 2015) or cancer stem cell theory (Laplane 2016). Although these suggestions have led 
to valuable research programs, they miss the key issue at the root of the difficulties facing 
cancer translational research: the conceptualization of causation in cancer. 
The central thesis of this paper is that cancer translational research needs a new 
perspective on causation. In the next section (Section 2), I review two predominant approaches 
to investigating cancer (the molecular biomarker approach and the evolutionary medicine 
approach), as well as dissect their causal frameworks. Then in Section 3, I argue that the 
frameworks are insufficient because they map on to Ernst Mayr’s proximate-ultimate distinction, 
which is an inadequate conceptualization of cancer’s causation in biological systems. In Section 
4, I suggest that this problem can be solved through a notion of modularity, by drawing an 
analogy to evolutionary developmental biology. I apply modularity directly to cancer translational 
research in Section 5. 
 
2. Predominant Approaches and Frameworks for Investigating Cancer 
 
2.1. Molecular biomarker approach 
 Biomedical research has become increasingly molecular with the availability of 
technologies such as whole genome sequencing. The promise has been that a better 
understanding of molecular mechanisms will make targeted clinical interventions possible. 
These interventions modify or correct abnormalities in particular individuals while minimizing 
side effects that come with traditional blanket treatments such as chemotherapy. The focus on 
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targeted interventions in individuals has fueled the rise of precision1 medicine (Collins and 
Varmus 2015). One version that has become widespread is based on sequencing the genomes 
of individuals. The goals for this endeavor are to identify and develop drugs that will be effective 
for the patient based on their specific genomic composition. Because genomes can be 
sequenced, scanned, and compared quickly and (relatively) inexpensively, researchers look for 
variants that are biological markers (biomarkers) of diseases. These variants are supposed to 
then be differences between healthy and sick individuals that give insight into how patients will 
react to drugs, which allows for tailored prescriptions and dosages. 
 One of the most successful examples of the molecular biomarker approach is 
trastuzumab, also known as Herceptin (Genentech).2 The FDA approved trastuzumab for the 
treatment of metastatic breast cancer in 1998 (Ignatiadis et al 2009), and it has been heralded 
as having a profound impact on the care of HER2+ breast cancers3 (Hudis 2007), and as “a 
major advance in targeted cancer therapies” (National Breast Cancer Coalition 2013). 
Trastuzumab is a humanized monoclonal antibody with two binding sites specific to the 
extracellular portion of HER2, a cell surface protein associated with the formation of 
homodimers as part of a cell growth signal pathway. When HER2 is overexpressed, the 
homodimers continually signal cells to grow and divide. Trastuzumab binds to the HER2 protein 
and blocks dimerization, which prevents further activation of signaling. Additionally, the antibody 
triggers the immune system to target HER2+ cells with increased antibody-dependent cell-
mediated cytotoxicity (Hudis 2007). 
                                                 
1 Though precision medicine and personalized medicine are different endeavors, there is much 
overlap between the two and the term ‘precision medicine’ is replacing the use of ‘personalized 
medicine’ (Katsnelson 2013).  
2 Imatinib (Gleevec), used to treat chronic myeloid leukemia (CML), is by far the most successful 
example of a targeted cancer therapy. However, CML is caused by a single chromosomal 
rearrangement, which means its causal dynamics are not widely applicable to other cancers. 
3 Breast cancers are classified as HER2+ when there is an overexpression of the membrane-
bound HER2 (Human Epidermal Growth Factor Receptor type 2) protein. HER2+ breast 
cancers comprise 20-30% of invasive breast carcinomas, and these patients have decreased 
overall survival (Hudis 2007). 
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 This example shows how the molecular biomarker framework can work. Researchers 
identified a mechanism (a cell growth signaling pathway), which is causally relevant to 
carcinogenesis, and a specific biomarker (the HER2 protein) where a targeted intervention 
should substantially make a difference. Original clinical trials with HER2+ metastatic breast 
cancer patients showed positive results in 12-25% of the cases, depending on previous 
treatment regimes, thus showing a proof of principle for the effectiveness of trastuzumab. In 
later trials, when administered in an adjuvant setting (i.e., trastuzumab plus chemotherapy), the 
risk of recurrence dropped by 40-50% and the risk of death dropped by one-third (Ignatiadis et 
al 2009). In comparison to most cancer treatments, these results are impressive. But, given the 
straightforward nature of the intervention, greater response rates were expected. Additionally, 
further analyses suggest that the chemotherapy accounts for much of the efficacy (Moja et al 
2012). Some anticipate that identifying more tumor characteristics (including more biomarkers) 
will lead to better efficacy (Ignatiadis et al 2009). Others have suggested that the limited efficacy 
is due to misplaced attention on HER2 expression. That is, HER2 expression is a bad proxy. 
Karamouzis and colleagues (2007) suggested that heregulin, a ligand that binds to HER2 (and 
other) dimers, might be a better biomarker than HER2 overexpression. 
 The fact that trastuzumab was developed to treat invasive or metastatic cancer but 
shown to be effective only in early stage cancers4 says something significant about the causality 
of cancer. The molecular biomarker approach might work if its target was part of a relatively 
static system, but diseases like cancer are dynamic and progressive. Molecular biomarker 
approaches ignore the developmental nature of cancer in individuals, and of disease biology 
more generally. Disease-affected systems in individuals are complex and have evolved robust 
and redundant pathways in order to address circumstances of disturbance. To investigate and 
                                                 
4 Trastuzumab is still used to treat metastatic HER2+ breast cancers but in combination with 
other therapies targeted at stopping HER2 from forming dimers with other ligands (Baselga et al 
2012). 
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understand these complex systems, many multilevel and integrated approaches are needed to 
account for causal dynamics involving feedback loops and robustness at different levels and 
across different time scales (Mitchell 2009). The molecular biomarker approach alone is 
insufficient. 
 
Molecular biomarkers as difference makers 
 In order to see why the molecular biomarker approach is insufficient, it is important to 
look at the causal framework employed. Recall that this approach involves finding the molecular 
differences between healthy and unhealthy individuals or tissues and then intervening on those 
differences to change the resulting phenotype. Thus, the molecular biomarker is what makes 
the difference between being healthy and unhealthy. 
Many experiments designed to understand causal structures are modeled on methods 
following John Stuart Mill’s methods of difference: if you have two identical systems differing in 
only one factor, then differences in outcome can be attributed to that differing factor. Under 
these conditions, the factor is a difference maker. Knockout experiments are a widely used form 
of this causal reasoning strategy. For example, to infer the role of the gene TP53 in cancer, one 
can compare standardized mice, some of which have TP53 inactivated and some with 
functioning TP53. If mice with inactivated TP53 show abnormal cell development that results in 
tumors, whereas the mice with functioning TP53 show normal cell development, then, assuming 
all other factors are equal5, we can infer that the TP53 gene plays a causal role in cell 
development (Mitchell 2009). James Woodward’s interventionist account of causation 
(Woodward 2010) is a more formal description of the causal framework of difference-making 
relevant to the molecular biomarker approach: 
                                                 
5 This is the reason to use standardized mice. These mice are inbred to be genetically identical 
and raised in the same environments. This underwrites the assumption is that everything is 
identical, except for the knocked-out gene. 
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X causes Y if and only if there are background circumstances B such that if some 
(single) intervention that changes the value of X (and no other variable) were to 
occur in B, then Y or the probability distribution of Y would change. 
 
Using standardized mice in knockout experiments is a way to achieve the same background 
circumstances (B). The variable X takes two values: functioning TP53 and inactivated TP53. 
The variable Y takes on two values as well: normal cell development and abnormal cell 
development. This gives the following causal formulation: if one intervenes on TP53 and 
changes its value from functioning to inactivated, and the value of the normal cell development 
changes to abnormal, then one can infer that TP53 causes (i.e., make a difference to) normal 
cell development. An important part of this formulation is the attention put on a particular place 
where a specific intervention can be made by the researcher to change the outcome of the 
causal processes, assuming that B remains fixed. 
 Despite the value of this causal framework, there are several limiting assumptions 
related to its application to different areas of medicine. The first assumption is that there is a 
one-to-one relationship between the variant and the disease phenotype; i.e., ‘X causes Y’, not 
‘X and Z cause Y’ or ‘X causes Y and W’. Many-to-one relationships (‘X and Z cause Y’), either 
as multiple pathways resulting in the same phenotype or many causal factors contributing to 
one phenotype, can make it difficult to know where to intervene because these cases facilitate 
redundancy in the system that, in some cases, compensates for the change. Additionally, 
interventions on one-to-many or many-to-many relationships (‘X causes Y and W’ or ‘X and Z 
cause Y and W’), such as genes showing pleiotropic effects in two or more seemingly unrelated 
pathways or phenotypes, can lead to unwanted outcomes. In other words, it is difficult to change 
X without affecting other variables. Thus, redundant pathways and pleiotropy will constrain the 
success of the difference-making causal framework used in the molecular biomarker approach. 
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 A second assumption is that the background conditions remain the same when you 
change the value of the variable (e.g., from functioning TP53 to inactivated TP53). That is, to 
test if functioning TP53 makes a difference on normal cell development, one needs a group of 
individuals with functioning TP53 and a group of individuals with inactivated TP53. Additionally, 
for this causal framework to apply, the activation of TP53 has to be the only difference. This 
might be possible (or close to possible) in laboratory conditions with the use of standardized 
model organisms or cell cultures, but in the clinical setting this assumption does not hold. The 
same mutation can be malignant in one individual, but not in another depending on the genomic 
background or previous mutations (Greaves and Maley 2012). The variation from one individual 
to another often violates the condition that the background conditions are similar, and the partial 
effectiveness of Trastuzumab in treating breast cancer illustrates this clearly. 
 Finally, the difference-making framework tends to treat all difference-making factors 
symmetrically. That is, it is assumed that all difference-makers in that system will affect the 
outcome in similar ways, and there is no principled way to choose which factor(s) to privilege. 
However, not all causal factors play symmetrical roles in biological systems. Woodward (2010) 
suggests that knowledge of other characteristics of causal relationships, such as stability and 
specificity, will lead to more nuanced pictures of different causal relationships, though the 
conditions for stability and specificity are less precisely characterized than those for difference-
making. Interventions relevant to the clinical treatment of cancer (e.g., via surgery or 
chemotherapy) require not only that a factor be identified as an actual difference-maker (versus 
a potential difference-maker), but also detailed knowledge of how it makes a difference (e.g., 
stability and specificity). Thus, identifying actual difference-makers permits the identification of 
multiple causes relevant to tumor progression or other aspects of cancer (Waters 2007), but 
does not, on its own, suggest further characteristics that would facilitate clinical applications.  
 It is important to note that cancer researchers may or may not think that these three 
assumptions–there are one-to-one causal relationships, background conditions are sufficiently 
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similar, and identifying difference-makers alone is adequate–are appropriate or true of the 
world. The point is that they are assumptions of the causal framework used to identify molecular 
biomarkers. Regardless of whether all of the researchers share each of the assumptions of the 
causal framework, they are embedded in the molecular biomarker approach. These 
methodological assumptions help to explain why this approach is insufficient to dissect cancer’s 
complex causal dynamics. 
 
2.2 Evolutionary medicine approach 
 Towards the end of the 20th century, a group of clinicians joined forces with a group of 
evolutionary biologists to reconnect medicine and evolutionary biology. Although a driving 
aspect of this enterprise was incorporating evolutionary biology into medical school curricula 
(Williams and Nesse 1991; Nesse and Schiffman 2003; Nesse 2008; Nesse et al 2010), the 
main research goals were to derive new insights into both medical and evolutionary questions, 
as well as change clinical practices (Williams and Nesse 1991; Nesse 2001; Nesse and Stearns 
2008; Valles 2012; Stearns 2012). For example, can an evolutionary approach answer why 
particular symptoms appear? Why are certain individuals more susceptible to certain diseases 
(Nesse 2001; Nesse et al 2006; Nesse and Stearns 2008; Nesse et al 2010)? How should 
answers to these questions modify patient care? 
 Evolutionary medicine has answered many medical questions utilizing population 
genetic theory and an adaptationist research program (Nesse and Stearns 2008; Nesse 2008; 
Valles 2012). An important example is explaining the prevalence of sickle cell anemia through 
heterozygote advantage. Individuals that are homozygous for the recessive sickle-cell allele 
(SS) suffer from sickle-cell anemia, which is usually fatal due to the formation of blood clots and 
decreased oxygen delivery to tissues. Individuals that are homozygous for the dominant allele 
(AA) have normal red blood cells but are susceptible to malaria. Those that are heterozygous 
(AS) have both normal and sickled red blood cells, and have increased resistance to malaria, as 
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the sickled phenotype makes the red blood cells less suitable for the malaria-causing parasite. 
In environments where malaria is epidemic (e.g., many regions of Africa), the AS genotype is 
more fit than either the AA or the SS genotypes. Therefore, under these environmental 
conditions, the S allele will be maintained in the population and sickle-cell anemia will continue 
to persist. Note that this explains the persistence of sickle cell anemia but does not suggest any 
changes to clinical practices. 
 Antibiotic resistance, on the other hand, is common example used to demonstrate 
medically-relevant evolution in real time (Stearns 2012) and also has potential for clinical 
application. Resistance was long thought to be a result of evolved coexistence with the host. But 
selection leads to higher virulence of pathogens, in part due to rapid parasite evolution (Williams 
and Nesse 1991; Nesse and Stearns 2008; Nesse 2008), and thus clinical efforts to minimize 
resistance were misinformed previously. By administering large doses of antibiotics to reduce 
the chance of de novo resistance mutations occurring, clinicians were actually selecting for rare 
resistance genes already present in the population, which could then be horizontally transferred 
to otherwise susceptible bacteria. This has led to more discussions about the use of antibiotics 
in hospitals and clinics, including how to balance the killing of bacteria of an infection without 
strongly selecting for existing drug-resistant bacteria (Smith et al 2014). 
 A key contrast between the molecular biomarker approach and the evolutionary 
medicine approach is that the former concerns individuals and the latter populations. However, 
the examples of sickle-cell anemia and antibiotic resistance show that the appropriate level at 
which to consider “the population” in evolutionary medicine can vary from populations of people 
(e.g., in the sickle-cell anemia case) to populations of cells (or populations of microbes in the 
antibiotic resistance case). With respect to cancer, it is no different. For populations of people, 
mismatches between past and current environmental contexts can explain the persistence of 
vulnerabilities to cancer (Greaves 2002; Aktipis and Nesse 2013). Additionally, population 
genetics can be applied to cancer incidence data to test hypotheses about the causal roles of 
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mutation and drift in cancer (Frank 2007). This informs predictions about when incidence curves 
will shift, and thus when to start screening for particular cancers in certain populations. 
 With respect to populations of cells, Peter Nowell proposed a model of clonal evolution 
in tumors in which they develop over time through a series of stepwise somatic mutations 
followed by repeated selection (Nowell 1976). A mutation occurs in a somatic cell (either 
spontaneously or induced by a carcinogen) that gives it a growth advantage over neighboring 
cells and facilitates the clonal expansion of cells containing that mutation. As the population of 
cells expands, more mutations accumulate, some of which will give additional selective 
advantages, allowing those subpopulations with the advantage to be selected for and further 
expand. This process results in tumors that reflect specific and local environmental pressures. A 
more nuanced account of this process treats the tumor as a byproduct of the tissue ecosystem 
(Greaves and Maley 2012). Each time a treatment (e.g., chemotherapy) is given, it changes the 
ecosystem, which changes the development of the tumor. As a result, if part of the tumor is 
removed, then the tumor that recurs is a different tumor than what was originally there. This 
model illuminates why there is variation within a tumor and differences between individuals with 
the same kind of cancer.  
 A primary goal of evolutionary medicine is to have clinical impact. By analyzing 
incidence data from populations of people, we can develop screening policies. By applying 
evolutionary theory to populations of cells, new treatment regimens are suggested, such as 
adaptive therapy, where the goal is to maintain tumors at a stable size rather than fully eliminate 
all cancer cells (Gatenby et al 2009; Enriquez-Navas et al 2016). Cytotoxic drugs select for 
resistant cells and create an environment where the resistant cells can proliferate, causing a 
tumor to become more aggressive and harder to treat. As with antibiotic resistance, 
investigating cancer through an evolutionary lens can lead to better uses of existing treatments. 
However, this approach yields little mechanistic information that is relevant for the development 
of new treatments. More poignantly, an evolutionary framework does not help treat metastasis, 
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the pathological form of cancer that is responsible for most deaths. The fact that an evolutionary 
medicine approach gives predictive power and thus offers preventive possibilities is incredibly 
important. However, not every case of cancer can be diagnosed early, nor should we 
necessarily depend on early detection and prevention (Narod et al 2015; Prasad et al 2015). 
Thus, we still lack effective approaches for the investigation and clinical treatment of cancer, 
especially metastatic cases. The evolutionary medicine approach alone is insufficient.  
 
Natural selection and population-level causes 
 Like with the molecular biomarker approach, it is useful to look at the causal framework 
employed by an evolutionary medicine approach. Population genetics is the basis of 
evolutionary medicine (Nesse and Stearns 2008; Nesse 2008), which means natural selection, 
mutation, drift, and migration are factors in its causal framework. However, in practice, 
evolutionary medicine prioritizes natural selection as a cause, making it an adaptationist 
program (Valles 2012). For example, its answer to why we are still vulnerable to certain 
diseases is that humans are “bundles of compromises shaped by natural selection … to 
maximize reproduction, not health” (Nesse and Stearns 2008, 28). That is, much of the research 
program focuses on maladaptations (Nesse 2005). Individual organisms in a population show 
heritable variation with fitness differences, but natural selection is a population-level cause (see, 
e.g., Millstein 2006). Consequently, the causal framework of evolutionary medicine does not 
speak to the condition of specific individuals in the population. 
 Notably, mutation, drift, and migration play more prominent causal roles in evolutionary 
approaches to cancer than in conventional evolutionary medicine (Merlo et al 2006; Aktipis and 
Nesse 2013). Mutations create the heterogeneity in a tumor allowing for faster progression and 
therapeutic resistance (Aktipis and Nesse 2013). Genetic drift occurs when population sizes are 
small. While tumors are generally large populations of cells, metastasis (the spread of cancer to 
other locations in the body) occurs via small clusters of cells which create population 
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bottlenecks (Aceto et al 2014). Additionally, cancer stem cell populations are usually composed 
of only a few cells (Baker et al 2014), which explains why deleterious mutations can go to 
fixation and why some tumors might be more aggressive than others. Migration plays several 
roles in cancer biology. One is related to mismatches between ancestral conditions and modern 
environments. For example, light-skinned individuals migrating towards the equator creates a 
mismatch between skin pigment and sun exposure, and thus changes their susceptibility to skin 
cancer (Aktipis and Nesse 2013). Migration might also be important in explaining metastasis, 
which inherently involves the migration of cells from one location to another. One model 
suggests that heterogeneity in a tumor selects for migratory cells (Chen et al 2011). Although 
these evolutionary insights into cancer complement what has been discovered in terms of 
molecular mechanisms, they have not yet had a clinical impact. They account for why it is 
important to catch and treat cancers early, but do not give mechanistic information that would be 
useful for treating existing cancers in specific individuals. As a consequence, evolutionary 
medicine approaches alone are insufficient to dissecting cancer’s complex causal dynamics.  
 
3. The problem of the proximate/ultimate distinction 
 
Combining the molecular biomarker and evolutionary medicine approaches? 
 Although both the molecular biomarker and evolutionary medicine approaches are 
necessary, neither is sufficient to dissect the causally complex dynamics of cancer, even when 
considered jointly. The approaches ask fundamentally different questions and therefore 
investigate causes using different frameworks. Researchers using the molecular biomarker 
approach want to know how cancers arise and progress in individuals, and how specific 
molecules make a difference to the outcome or phenotype. Alternatively, those using the 
evolutionary medicine approach want to know why cancers occur and progress, and why certain 
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populations are more susceptible. The causal framework differences between the approaches 
fall on opposite sides of Ernst Mayr’s proximate-ultimate distinction. 
 Mayr distinguished between two different kinds of causes: proximate and ultimate (Mayr 
1961). Proximate causes are those studied by functional biologists (e.g., physiologists and 
developmental biologists) and often answer “How?” questions. Explanations that come from this 
orientation involve immediate factors, such as day length or hormone levels. For example, a 
change in hormone levels causes an organism to change its behavior. In contrast, ultimate 
causes are those that involve evolutionary history and are present due to many generations of 
natural selection. These explanations are historical in nature and often answer “Why?” 
questions. For example, an organism has a behavior because it was beneficial to its ancestors 
and was selected for within a population over many generations. Mayr aimed to differentiate 
proximate and ultimate causes while arguing that both kinds of causes are necessary for a 
complete understanding of any biological phenomenon. Thus, according to Mayr, the molecular 
biomarker and evolutionary medicine approaches might together yield a complete causal 
framework for understanding causation in cancer. Although having both approaches does give a 
fuller causal picture than just one approach alone, there are reasons why we might not want to 
interpret the biomarker and evolutionary medicine approaches as separate or distinct in this 
way. 
 Kevin Laland and colleagues have argued that the distinction between proximate and 
ultimate causes, though helpful at times (e.g., it prevents scientists from talking past each other, 
allowed evolutionary biology and developmental biology to independently grow and mature as 
disciplines, etc.), has actually hindered progress in biology, particularly evolutionary biology 
(Laland et al 2011; Laland et al 2012). This is because the distinction has become entrenched 
as a truth about the nature of causation, rather than as a heuristic in the study of causes (Laland 
et al 2012); it has shifted from being a good way to approach causality in biological systems to 
being the only way one can understand causation in biological systems. The mentality has 
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become entrenched because Mayr’s basic premise–proximate and ultimate causes answer 
different questions and are not in competition with one another–implies that there is no reason 
to link them; proximate causation is not important to the investigation of ultimate causes and 
vice versa (Laland et al 2012). This makes it difficult for the approaches to mutually inform one 
another in a way that would contribute to clinically relevant outcomes. This mentality is 
manifested in cancer research, where the two approaches are funded through different avenues 
and the research communities rarely overlap. 
 Maintaining the proximate-ultimate distinction leads to other problems as well. First, 
Laland and colleagues argue that this distinction cannot account for cases of reciprocal 
causation (Laland et al 2011; Laland et al 2012). If developmental processes are interpreted as 
proximate causes and separated from evolutionary processes interpreted as ultimate causes, 
we miss the fact that developmental processes contribute to the phenotypes on which selection 
will act, and these mechanisms are under selection themselves. Thus, developmental 
processes (proximate causes) are both an input and an output of ultimate causes (e.g., 
selection). Second, the proximate-ultimate distinction and how-why distinction are false 
dichotomies because it is possible to ask questions that can be answered with both or neither 
category (Calcott 2013). More generally, it is not clear what it means for an explanation to be 
historical, which is presumed in the proximate-ultimate distinction. This affects the range of 
possible answers to ultimate questions and indicates that we are getting only partial answers or 
explanations. 
 While these are legitimate concerns, these and other critiques of the proximate-ultimate 
distinction arise mostly from those working on evolutionary questions. Evolutionary biologists 
are concerned about whether evolutionary theory needs to be extended to include 
developmental biology and other causes typically categorized in proximate causation (Laland et 
al 2014). But little to no critique of the distinction has come from developmental biologists. Do 
studies typically categorized as proximate causation (such as developmental biology) require 
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studies typically categorized as ultimate causation (such as evolutionary biology)? This is a 
more applicable question in the context of cancer translational research. 
 The molecular biomarker approach is predominant (by the amount of money allocated, 
number of research programs, papers, etc) in the methodology of developmental biology. 
Although discovering molecular mechanisms is essential for knowing where to intervene on 
individuals with cancer, an evolutionary perspective informs when to intervene on a population. 
But simply identifying or acknowledging the proximate-ultimate distinction does not facilitate 
bridging the causal frameworks of the two approaches. Each approach is complementary to the 
other, but just having both side-by-side is not enough. That is, there are probably important 
factors or dynamics that are being missed (e.g., reciprocal causation). The standard molecular 
biomarker and evolutionary medicine approaches do not fully capture the complex causal 
structure, even when considered jointly. We need a perspective on causation that integrates 
both developmental and evolutionary approaches to cancer in order to better understand cancer 
and identify effective clinical treatments. 
 
4. Bridging the proximate-ultimate divide through modularity 
 Bridging the proximate-ultimate divide is not a trivial task; proximate and ultimate causes 
are typically studied using different methodologies, work on vastly different time scales, and 
depend on different underlying conceptual foundations. Similar to cancer translational research, 
evolutionary developmental biology (evo devo) aims to explore the connections between the 
development of individual organisms and their evolutionary transformation to discover causal-
mechanistic explanations of individual traits involved in population-level events (Laubichler 
2007; Hamilton 2009). One way evo devo has pursued these connections is through the notion 
of modularity (von Dassow and Munro 1999). By analogy, I suggest that cancer research can 
benefit from looking to modularity as a way to reconceptualize causation in cancer. 
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Modules and modularity 
 Although there are many definitions of modularity, a module is generally considered to 
be an entity or part that is discrete or autonomous in some ways but integrated within a larger 
whole (usually the rest of the organism) in other ways (Wagner et al 2007). Modules can be 
processes or structures (Raff 1996), and be instantiated at any hierarchical level. Examples 
include: fragments of cis-regulatory DNA (Arnone and Davidson 1997), morphogenic fields, 
signal transduction pathways, gene regulatory networks (Gilbert and Bolker 2001), and leaf 
primordia (Gass and Bolker 2003). Furthermore, organisms themselves can be considered 
modules of higher-level individuals, such as superorganisms (Schlosser and Wagner 2004). 
Thus, modules can be embedded in higher-order modules (Schlosser 2004). 
 Modularity involves part-whole relationships, but various fields think about these 
relationships differently. Evolutionary biologists consider modules to be dissociable subunits or 
parts of a larger system, typically the adult organism (Gass and Bolker 2003). Evolutionary 
modules are parts autonomous enough to change without appreciably changing other aspects 
of the organism. Rasmus Winther (2005) calls this a partitioning strategy, where you can 
understand the whole as a sum of the parts. On the other hand, developmental biologists refer 
to modules as collectives of entities and processes that act in some unified way to perform a 
function (Bolker 2000). In this view, a strategy of articulation is used when the relationship or 
interactions between parts is just as important, if not more, than the parts themselves (Winther 
2005). For evolutionary approaches, the autonomy of a module is usually foregrounded, 
whereas in developmental approaches, the interactivity or integration between modules is more 
important. 
 Evo devo combines these approaches to modules so that evolutionary modules are the 
phenotypes that result from particular developmental modules (Gass and Bolker 2003). 
However, there is not a one-to-one relationship between developmental modules and resulting 
evolutionary modules (Bolker 2000; Schlosser and Wagner 2004); multiple modules of the same 
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type can be used in a single pathway or process, or modules can overlap by sharing elements 
(Schlosser 2004). Thus, what is critical for evo devo researchers in bridging developmental and 
evolutionary approaches is how modules are individuated and interact with one another. Once 
meaningful modules are identified, the interactions between them become the focus because it 
is the changes in interactions that result in phenotypic differences and therefore evolutionary 
change6. 
 Using modularity as a way to bridge different causal frameworks forces us to shift our 
attention in two main ways. First, as was discussed above, we shift our attention away from 
investigative strategies that are specific to proximate or ultimate causation, and thereby avoid 
treating proximate and ultimate causation separately. Second, as I will discuss below, a causal 
perspective based on modularity inherently requires the consideration of relationships between 
multiple levels of organization and across different time scales.  
 
5. Cancer translational research and the causal framework of modularity 
 It is important to emphasize that my argument is not that a modularity-based causal 
perspective can or should bridge the proximate-ultimate distinction across biology generally, but 
rather that it can bridge the proximate and ultimate causal frameworks in cancer translational 
research specifically. As noted, there are multiple ways to conceive of modularity–by focusing 
on the autonomy of the modules, the interactivity, or the changes in interactions. Since cancer is 
both a developmental and evolutionary phenomenon, I continue with evo devo’s approach to 
modularity–modularity can occupy the spaces of both proximate and ultimate frameworks, thus 
bridging the divide and highlighting the causal complexity of cancer. 
                                                 
6 The agnathan-to-gnathostome transition is a good example of this, where heterotopic (spatial) 
shifts in developmental modules resulted in the gnathostome-type oral apparatus in which both 
the upper and lower jaws are derived from the mandibular arch. In contrast, only the lower lip of 
the agnathan is derived from the mandibular arch. The upper lip is derived from the 
premandibular module (Kuratani 2009). 
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 Evo devo’s interpretation of modularity was not meant to replace the evolutionary or 
developmental interpretations with an intermediate notion, but rather allow for the discussion of 
modularity at multiple levels and across time scales which requires being clear about which 
notion of modularity is being used for investigation. For example, one can have discussions 
about modularity at the level of individuals or populations. Thus, having a causal perspective 
based in modularity requires first identifying meaningful modules for investigation. There are 
many potentially meaningful modules in cancer – molecular pathways, cells, tumors, tissues, the 
circulatory system, the immune system, and many more. By conceptualizing causation in cancer 
through modularity, the changes in the interactions between identified modules as the cancer 
progresses (or regresses), take on a new significance. Cells normally interact in specific ways to 
form tissues, but when a cell gains enough autonomy (i.e., it becomes highly modular) to defect 
from or cheat within the tissue, there is the possibility for it to become cancerous. As the cell 
grows into a tumor, it progressively loses some autonomy and becomes integrated with other 
cells in the tumor. As the tumor continues to grow such that nutrient and waste transport 
become important, its dependence on angiogenesis (the development of new blood vessels) 
and interactivity with the circulatory system change. Additionally, when treatment is 
administered (especially immunotherapy), the cancer forms a different complex, iterative 
relationship with the immune system. The interactions between modules and the relationships 
between the parts and whole are constantly changing depending on the tumor 
microenvironment, as long as the cancer exists. These multilevel changes in relationships 
across different time scales facilitate and constrain the evolvability of the cancer in certain ways, 
thus affecting any possible cancer-related treatments. 
Additionally, knowing which parts of the organism to consider as meaningful parts and 
wholes is only possible if cancer is considered with a temporal aspect. Different modules 
become important during different stages of cancer progression. During tumorigenesis, the 
meaningful part might be the cell and the meaningful whole might be the tissue in which that cell 
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resides. Later in tumor growth, the meaningful relationships to study might be between the 
tumor and the circulatory system. Furthermore, during metastasis (the spread of cancer to new 
locations in the body), it might be important to investigate the relationships between the clusters 
of cells that break off, the circulatory system through which they travel, the immune system from 
which they must evade, and the new tissues in which they ultimately plant. 
Major transitions in the progression of the cancer (e.g., from localized tumor growth to 
metastasis) are especially important places to find meaningful changes in interactions that could 
be manipulated for interventions. Tracking modular, multilevel causal interactions through 
different time scales in the progression of cancer has the potential to open up novel clinical 
treatment options that were previously hidden in the divide between proximate and ultimate 
causation. For example, immunotherapy appears to bridge proximate and ultimate perspectives 
by striving for the precision of the biomarker approach but also taking advantage of the evolving 
immune system to combat evolving cancerous systems. Researchers want to find proteins that 
are over-expressed in all and only cancer cells (such as PD-L1; (Iwai et al 2002)) across all time 
points so that the immune system can continue to target and kill the cancer cells regardless of 
how the cancer evolves or its state of progression. However, if we apply what I have discussed 
here regarding the complexity of multilevel causal interactions across time, we can see there is 
still much more work to be done in order to predict and manage the side effects (e.g., 
autoimmune disorders) and potential complications or failures of immunotherapies (especially 
regarding metastasis and recurrent tumors). 
Remember that modules can be embedded within other modules and modularity is 
found on a spectrum–any given module can be more or less modular than another module–and 
the degree of modularity can change given changes in interactions. Modules that are less 
modular will be affected more when interactions between modules change than modules that 
are more modular. Thus we can expect that that as a given cancer progresses, we have to shift 
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which modules get highlighted. But we cannot forget that the relevant modules are interacting 
with other modules, as is the worry with the development of autoimmune disorders.  
Reconceptualizing the causation of cancer through modularity requires that 
developmental and evolutionary questions be asked and answered to know which modules are 
worthy of attention. For example, questions about evolvability follow directly from a modularity-
based framework because modularity is one among many ways for core molecular processes to 
confer evolvability (Kirschner and Gerhart 1998). If evolutionary medicine approaches desire to 
make a clinical impact, studies need to be prospective as well as retrospective. Generally, 
understanding the molecular mechanisms that are both causes and consequences of changes 
in modularity will be informative for understanding how changes in modularity affect evolvability. 
This also applies to cancer translational research, where meaningful interpretations of identified 
molecular biomarkers of cancer along with the predictive work from evolutionary medicine can 
be translated into clinical applications. 
 
6. Conclusion 
 The molecular biomarker and evolutionary medicine approaches to cancer translational 
research use widely accepted methods of investigation and explanation in biology and 
biomedical research. These approaches lend themselves well to the current scientific culture as 
they produce quick results for publications and grants, and ultimately give simple and clean 
explanations that are easy to understand and convey to others, including the general public. 
However, they only occasionally produce or lead to “successful” interventions. Additionally, 
these interventions only help a small percentage of the population (see the herceptin discussion 
above), or are quite far from clinical implementation (e.g., adaptive therapy). Therefore, 
following Mayr’s suggestion to have separate proximate and ultimate causal frameworks does 
not work for cancer translational research, nor is it necessarily better than having just proximate 
or just ultimate causal frameworks. This is because cancer translational research requires more 
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than explanation and understanding. For example, knowing that you were more susceptible to a 
certain kind of cancer because of an upregulated pathway that gives those cells a fitness 
advantage does not tell one where to intervene in order to prevent or eliminate the cancer. In 
other words, the evolutionary medicine population approach does not isolate difference makers. 
Furthermore, oncologists and society alike would prefer interventions that work without first 
almost killing the patient (in theory, enough radiation or chemotherapy would kill all of the 
cancer cells, but the number of healthy cells also killed is far greater than zero). If the goal is 
effective and relatively safe interventions, we need a framework that embraces the causal 
complexity of cancer biology and transforms proximate and ultimate investigative strategies into 
one more cohesive and fuller explanation. 
 In this paper, I proposed a novel perspective on causation in cancer through the notion 
of modularity. I argued that the standard research programs fall too neatly along the Mayr 
proximate-ultimate distinction, but that in the context of cancer translational research, this 
distinction can be bridged through the notion of modularity. The multiple notions of modularity 
play a translational role that allows for an expansion of the set of causes one can consider in 
cancer translational research, so long as one is clear about which notion is being employed. 
Similar to what has been done within evo devo, the notion of modularity allows cancer 
translational researchers to have discussions that consider both proximate and ultimate causes 
at the level of the individual or population. By understanding mechanisms through which the 
relationships between various modules (cell, tumor, tissue, immune system, etc) change over 
different scales of time, cancer translational researchers can better comprehend the complexity 
of the molecular data as well as use the evolvabilities of different cancers to proactively develop 
treatment regimes, rather than continue to treat patients reactively. 
 Both of the current predominant approaches suggest catching and treating cancers early 
is the best option. Though shown true in some cases, this is not always possible, nor always the 
best option (see, e.g., Narod et al. 2015; Prasad et al. 2015). Therefore, it is essential to 
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develop treatment regimens for advanced and metastatic cancers. The modularity-based causal 
perspective described here is one way forward for a research program in cancer translational 
research that does not deny the vast amounts of existing data, but provides a path to discover 
and interpret these results for more effective treatments and foster future investigations that 
identify novel clinical applications. 
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